ZEPZELCA

What is this medication? ZEPZELCA, which contains the active ingredient lurbinectedin, is a prescription medication used to treat adults with a specific type of lung cancer known as small cell lung cancer. It is specifically indicated for patients whose cancer is metastatic, meaning it has spread to other parts of the body, and has progressed after they have already received treatment with platinum-based chemotherapy. This medication was granted accelerated approval by the FDA based on its potential to shrink tumors, though further clinical trials may be required to fully verify its long-term benefits.

The drug works as an alkylating agent by binding to the DNA within cancer cells. By attaching to the minor groove of the DNA double helix, it interferes with the cells' ability to multiply and eventually leads to their death. ZEPZELCA is typically administered by a healthcare professional as an intravenous infusion in a clinical setting once every twenty-one days. Patients receiving this treatment are monitored closely for potential side effects, such as low blood cell counts or liver toxicity, as part of their ongoing oncology care.